Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Kanayama Y, Naganuma A, Nishina S, Otsuka M, Kobara H, Kawashima H, Takayama T, Kawaguchi T, Yamasaki T, Takami T; Hepatology InVestigator Experts in Japan (HIVE-J) Study Group.
Saeki I, et al. Among authors: yamasaki t.
PLoS One. 2024 Sep 25;19(9):e0311084. doi: 10.1371/journal.pone.0311084. eCollection 2024.
PLoS One. 2024.
PMID: 39321197
Free PMC article.